Clinical trial

A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)

NCT07371468

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention GSK5926371 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-02-10

PhasePHASE1

Conditions

Systemic Lupus Erythematosusverified · MONDO: systemic lupus erythematosus

Interventions

GSK5926371BIOLOGICAL

Sponsors & collaborators

GlaxoSmithKlinelead sponsor

Mapped research locations

MadridSpain2 BarcelonaSpain1 TaipeiTaiwan1 WarsawPoland1 ToulouseFrance1 Buenos AiresArgentina1 BordeauxFrance1 PoznanPoland1 São PauloSão Paulo, Brazil1 FukuokaJapan1 HiroshimaJapan1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07371468 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.